Femasys (FEMY) Stock Price, News & Analysis

Company Overview

Femasys International, Inc. is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography. This system is intended to facilitate earlier and more accurate diagnosis of intrauterine abnormalities such as polyps, fibroids and adhesions. Femasys is also developing a pipeline of complementary devices aimed at expanding its portfolio of interventional gynecological tools.

Femasys is listed on the Nasdaq under the ticker symbol FEMY and is incorporated in Delaware with principal executive offices in Beijing, China. The company’s leadership team includes medical device veterans with deep experience in product development, regulatory affairs and commercial strategy. Femasys continues to pursue regulatory clearances in key markets, including CE marking in Europe, while exploring opportunities to introduce its technologies across Asia, North America and other regions.

Key Stats

• Today's Range: $3.21 to $3.43
• 50-Day Range: $2.16 to $4.35
• 52-Week Range: $2.02 to $22.20
• Volume: 66,804 shs
• Average Volume: 2.15 million shs
• Market Capitalization: $27.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.00
• Consensus Rating: Moderate Buy

Femasys Stock Analysis - MarketRank™

Femasys scored higher than 65% of companies evaluated by MarketBeat, and ranked 261st out of 916 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Femasys has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Femasys has a consensus price target of $50.00, representing about 1,433.7% upside from its current price of $3.26.

Amount of Analyst Coverage

Femasys has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Femasys is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Femasys is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Femasys has a P/B Ratio of 6.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.63% of the float of Femasys has been sold short.

Short Interest Ratio / Days to Cover

Femasys has a short interest ratio ("days to cover") of 1.58, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Femasys has recently increased by 64.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Femasys does not currently pay a dividend.

Dividend Growth

Femasys does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Femasys has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Femasys this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for FEMY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Femasys to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of Femasys in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $124,000.00 in company stock, which represents 0.4539% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Femasys insiders have bought more of their company's stock than they have sold. Specifically, they have bought $124,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

7.75% of the stock of Femasys is held by insiders.

Percentage Held by Institutions

65.27% of the stock of Femasys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/01/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:FEMY
• CIK: 1339005
• Web: www.femasys.com
• Phone: 770-500-3910
• Fax: N/A
• Employees: 30
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Femasys: $50.00
• High Price Target: $130.00
• Low Price Target: $10.00
• Potential Upside/Downside: +1,433.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.63 million
• Net Margins: -534.36%
• Pretax Margin: -511.61%
• Return on Equity: -225.97%
• Return on Assets: -74.68%

Debt

• Debt-to-Equity Ratio: 0.89
• Current Ratio: 2.14
• Quick Ratio: 0.55

Sales & Book Value

• Annual Sales: $2.29 million
• Price / Sales: 11.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 6.79

Miscellaneous

• Outstanding Shares: 8,380,000
• Free Float: 7,726,000
• Market Cap: $27.32 million
• Optionable: Not Optionable
• Beta: -2.07